Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$93.36 USD
+0.54 (0.58%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $93.34 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$93.36 USD
+0.54 (0.58%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $93.34 -0.02 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Zacks News
Deciphera Pharmaceuticals, Inc. (DCPH) Down 9.7% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Iovance Biotherapeutics (IOVA) Down 21.2% Since Last Earnings Report?
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Blueprint Medicines (BPMC) Down 2% Since Last Earnings Report?
by Zacks Equity Research
Blueprint Medicines (BPMC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Blueprint (BPMC) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Blueprint (BPMC) reports better-than-expected second-quarter 2023 results, driven by increased Ayvakit sales, following FDA approval in a new indication.
Blueprint Medicines (BPMC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
Although the revenue and EPS for Blueprint Medicines (BPMC) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 15.12% and 27.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Blueprint's (BPMC) Q1 Earnings & Sales Top Estimates, View Up
by Zacks Equity Research
Blueprint Medicines (BPMC) announces better-than-expected results for first-quarter 2023 as it beats estimates for both earnings and revenues. Stock surges 13% following the news.
Blueprint Medicines (BPMC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 19.17% and 48.18%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Will Y-mAbs Therapeutics, Inc. (YMAB) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate Blueprint Medicines (BPMC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Blueprint Medicines (BPMC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Horizon Therapeutics (HZNP) Down 0.9% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Editas (EDIT) Down 21% Since Last Earnings Report?
by Zacks Equity Research
Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Deciphera (DCPH) Gets Breakthrough Tag for Qinlock Expanded Use
by Zacks Equity Research
The FDA grants breakthrough tag to Qinlock for treating second-line GIST patients with mutations in KIT Exon 11 and 17/18. Stock up on Tuesday in response.
Blueprint's (BPMC) Q4 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Blueprint Medicines (BPMC) announces better-than-expected financial performance in fourth-quarter and full-year 2022. Stock up in the aftermarket hours, following the news release.
Biotech Stock Roundup: BIIB's Q4 Results, EBS and BPMC Offer Updates
by Zacks Equity Research
Earnings results from Biogen (BIIB) and updates from EBS are the key highlights from the biotech sector during the past week.
Blueprint Medicines (BPMC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of 2.93% and 18.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Drug/Biotech Stocks Q4 Earnings Due on Feb 16: ALKS, RARE & Others
by Zacks Equity Research
Let's look at the four biotech/drug companies slated to release quarterly results on Feb 16.
Blueprint's (BPMC) Cancer Study Put on Partial Hold by FDA
by Zacks Equity Research
Blueprint's (BPMC) early- to mid-stage study for the treatment of patients with CDK2-vulnerable cancers put on partial clinical hold by the FDA.
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Blueprint Medicines (BPMC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Can Blueprint Medicines (BPMC) Climb 61.38% to Reach the Level Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 61.4% in Blueprint Medicines (BPMC). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Blueprint Medicines' (BPMC) Aykavit sNDA Gets FDA Priority Tag
by Zacks Equity Research
The FDA accepts and grants priority review to Blueprint Medicines' (BPMC) sNDA for the label expansion of Aykavit for indolent systemic mastocytosis.
Deciphera (DCPH) Rises 70% in the Past 6 Months: Here's Why
by Zacks Equity Research
Deciphera's (DCPH) Qinlock, approved for treating advanced gastrointestinal stromal tumors, has seen strong uptake since its approval. The recent restructuring initiative is saving costs.
ADC Therapeutics SA (ADCT) Stock Jumps 21.8%: Will It Continue to Soar?
by Zacks Equity Research
ADC Therapeutics SA (ADCT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Strength Seen in Fate Therapeutics (FATE): Can Its 9.3% Jump Turn into More Strength?
by Zacks Equity Research
Fate Therapeutics (FATE) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Apellis Pharmaceuticals, Inc. (APLS) Down 0.5% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.